← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...
HomeStocksARDTPrice Target
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

Ardent Health Partners, LLC (ARDT) Price Target Analysis

Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026

Current Price
$9.39
Market reference
Price Target
$14.57
+55.2% Upside
Target Range
$12.00 — $19.00
Wide divergence
Analyst Rating
Buy
12 analysts
Forward P/E7.4x
Trailing P/E5.9x
Forward PEG0.10
Implied Growth-12.4%
Median Target$14.00
Analyst Spread48.0%

Analysts see +55.2% upside to their consensus target of $14.57. The bullish rating consensus aligns with positive price target gap.

Price Forecast (1 Year)

Last 12 months price action with 12-month analyst target path

Current$9.39
Consensus$14.57
High$19.00
Low$12.00
Model$13.78
Bear Case
$12
+27.8%
Consensus
$15
+55.2%
Bull Case
$19
+102.3%
Valuation Model TargetsConfidence: 58/100
Bear$1
Base$14
Bull$4

Analyst Ratings Distribution

Breakdown of 12 published analyst recommendations for ARDT

25% hold / mixed conviction
+29
BearishBullish
Weighted analyst sentiment score based on 12 ratings
ConsensusBuy
Coverage12 Analysts
Net Score+29
Bull / Bear67% / 8%
Strong Buy00%
Buy867%
Hold325%
Sell18%
Strong Sell00%
Strong Buy
00%
Buy
867%
Hold
325%
Sell
18%
Strong Sell
00%
Recommendation Mix67% Buy · 25% Hold · 8% Sell
Buy (8)Hold (3)Sell (1)

ARDT Price Target Analysis

Updated February 28, 2026

As of February 28, 2026, Ardent Health Partners, LLC (ARDT) has a Wall Street consensus price target of $14.57, based on estimates from 12 covering analysts. With the stock currently trading at $9.39, this represents a potential upside of +55.2%. The company has a market capitalization of $1.34B.

Analyst price targets range from a low of $12.00 to a high of $19.00, representing a 48% spread in expectations. The median target of $14.00 aligns closely with the consensus average.

The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.

From a valuation perspective, ARDT trades at a trailing P/E of 5.9x and forward P/E of 7.4x. The forward PEG ratio of 0.10 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow -12.4% over the next year.

Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $13.78, with bear and bull scenarios of $1.05 and $3.53 respectively. Model confidence stands at 58/100, reflecting moderate uncertainty in projections.

Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.

Analyst Sentiment Comparison

Industry Peer Analysis
Avg Peer Upside+12.3%
Avg Forward P/E17.2x
Peers with Coverage8 / 9
CompanyMarket CapPriceTargetUpsideRatingFwd P/EAnalysts
ARDTArdent Health Partners, LLC
$1.3B$9.39$14.57+55.2%Buy7.4x12
HCAHCA Healthcare, Inc.$118.5B$529.70$523.92-1.1%Buy17.5x46
THCTenet Healthcare Corporation$21.0B$239.39$257.45+7.5%Buy14.1x32
MPWMedical Properties Trust, Inc.$3.2B$5.44$5.00-8.1%Hold47.6x28
ACHCAcadia Healthcare Company, Inc.$2.1B$23.44$19.82-15.4%Buy15.7x25
UHTUniversal Health Realty Income Trust$605M$43.62———25.2x—
CYHCommunity Health Systems, Inc.$485M$3.46$3.40-1.7%Hold—37
AUNAAuna S.A.$161M$5.34$7.63+42.9%Hold1.6x1
UHSUniversal Health Services, Inc.$3M$206.10$245.67+19.2%Hold8.8x43

Upside Potential Comparison

ARDT
+55.2%
AUNA
+42.9%
UHS
+19.2%
THC
+7.5%
HCA
-1.1%
CYH
-1.7%
MPW
-8.1%
ACHC
-15.4%

See ARDT's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is ARDT Undervalued?

See our Bear / Base / Bull DCF models and intrinsic value estimates.

View Valuation

Compare ARDT vs AGIO

See how ARDT stacks up against sector leader Agios Pharmaceuticals, Inc..

Start Comparison

Frequently Asked Questions

What is the ARDT stock price target for 2026?

The consensus Wall Street price target for ARDT is $14.57, representing 55.2% upside from the current price of $9.39. With 12 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.

Is ARDT a buy, sell, or hold?

ARDT has a consensus rating of "Buy" based on 12 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $14.57 implies 55.2% upside from current levels.

Is ARDT stock overvalued or undervalued?

With a forward P/E of 7.3798x, ARDT trades at a relatively low valuation. The consensus target of $14.57 implies 55.2% appreciation, suggesting meaningful undervaluation.

How high can ARDT stock go?

The most bullish Wall Street analyst has a price target of $19 for ARDT, while the most conservative target is $12. The consensus of $14.57 represents the median expectation. Our quantitative valuation model projects a bull case target of $4 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

How many analysts cover ARDT stock?

ARDT is moderately covered, with 12 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 3 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

What is the ARDT stock forecast?

The 12-month ARDT stock forecast based on 12 Wall Street analysts shows a consensus price target of $14.57, with estimates ranging from $12 (bear case) to $19 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $14, with bear/bull scenarios of $1/$4.

What is ARDT's fair value based on fundamentals?

Our quantitative valuation model calculates ARDT's fair value at $14 (base case), with a bear case of $1 and bull case of $4. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 58/100.

What is ARDT's forward P/E ratio?

ARDT trades at a forward P/E ratio of 7.4x based on next-twelve-months earnings estimates compared to a trailing P/E of 5.9x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Should I buy ARDT stock?

Wall Street analysts are very optimistic on ARDT, with a "Buy" consensus rating and $14.57 price target (55.2% upside). 8 of 12 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

Why do ARDT price targets vary so much?

ARDT analyst price targets range from $12 to $19, a 48% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $14.57 consensus represents the middle ground. Our model's $1-$4 range provides an independent fundamental perspective.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.